Clinical Trials Browser

Phase 1 × Prostatic Neoplasms × Panobinostat × Clear all

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00493766 2020-12-19

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Phase 1 Terminated

Prostatic Neoplasms

NCT00663832 2020-12-19

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Phase 1 Completed

Neoplasms, Prostatic Neoplasms

NCT00670553 2017-05-17

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Phase 1 Completed

GastrointestinalGenitourinaryHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT00419536 2010-04-08

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

Phase 1 Terminated

Prostatic Neoplasms